We are live on
!
Find out more
DAWN
Day One Biopharmaceuticals
DAWN
DAWN
Delisted
DAWN was delisted on the 22nd of April, 2026.
184 hedge funds and large institutions have $747M invested in Day One Biopharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 69 increasing their positions, 46 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% less ownership
Funds ownership: 92.95% → 92.94% (-0%)
30% less call options, than puts
Call options by funds: $1.23M | Put options by funds: $1.76M
37% less capital invested
Capital invested by funds: $1.19B → $747M (-$441M)
Holders
184
Holding in Top 10
2
Calls
$1.23M
Puts
$1.76M
Top Buyers
| 1 | +$23.3M | |
| 2 | +$16.7M | |
| 3 | +$12.5M | |
| 4 |
Millennium Management
New York
|
+$12.2M |
| 5 |
Goldman Sachs
New York
|
+$11.8M |
Top Sellers
| 1 | -$39.3M | |
| 2 | -$21.7M | |
| 3 | -$14.4M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$13.8M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
-$12M |